Form 8-K - Current report:
SEC Accession No. 0001213900-25-112184
Filing Date
2025-11-18
Accepted
2025-11-18 16:57:40
Documents
13
Period of Report
2025-11-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0266166-8k_apimeds.htm   iXBRL 8-K 24427
2 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT, DATED NOVEMBER 13, 2025 ea026616601ex10-1_apimeds.htm EX-10.1 10061
  Complete submission text file 0001213900-25-112184.txt   203753

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE apus-20251113.xsd EX-101.SCH 3017
4 XBRL LABEL FILE apus-20251113_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE apus-20251113_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0266166-8k_apimeds_htm.xml XML 3802
Mailing Address 100 MATAWAN RD SUITE 325 MATAWAN NJ 07747
Business Address 100 MATAWAN RD SUITE 325 MATAWAN NJ 07747 848-201-5010
Apimeds Pharmaceuticals US, Inc. (Filer) CIK: 0001894525 (see all company filings)

EIN.: 851099700 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42545 | Film No.: 251495596
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)